It is a pharma private limited company based in Mumbai, Maharashtra, India, established in 2006.
2006 | Mumbai, Maharashtra, India | ActiveNanotek Remedies Private Limited, a active private limited company, was established on 03 April 2006 in Mumbai, Maharashtra, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24231MH2006PTC160936. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹0.50 M and a paid-up capital of ₹0.50 M.
It upholds a compliant status. Its leadership includes Pramod Kumar Agarwal (Director), Santosh Agarwal (Director), Kundanika Singh (Director). Past directors included Ratan Kumar Singh, Shyama Singh. It holds no open charges and ₹7.75 M settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Row House 42-D, Mhada Complex, Near N.N.P. Zone 1 & 2, Off Film City Road, Goregoan East, ,, Mumbai, Maharashtra, 400065.
U24231MH2006PTC160936
160936
03 April 2006
₹0.50 M
₹0.50 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Nanotek Remedies Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pramod Kumar Agarwal | Director | 03 Apr 2006 | Current |
| Santosh Agarwal | Director | 03 Apr 2006 | Current |
| Kundanika Singh | Director | 05 Mar 2025 | Current |
| Shyama Singh | Additional Director | 01 Jan 2020 | Current |
| Kanishk Kanishk | Director | 05 Mar 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 10 Jun 2019 | Past |
| Pramod Abcsdd | Director | 10 Jun 2019 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nanotek Remedies Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 36.01% decrease. The company also saw a substantial fall in profitability, with a 3617.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 50.85%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2021, Nanotek Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹7,750,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Aug 2014 | Siemens Financial Services Private Limited | ₹3.35 M | Satisfied |
| 22 Feb 2012 | Allahabad Bank | ₹2.00 M | Satisfied |
| 23 Sep 2009 | Allahabad Bank | ₹2.40 M | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Nanotek Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nanotek Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nanotek Remedies's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Nanotek Remedies Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was completed.
Progress on Nanotek Remedies Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was documented.
Kundanika Singh was appointed as a Director was appointed as a Director on 05 Mar 2025 & has been associated with this company since 9 months 20 days . was recorded as a recent event.
Progress on Kanishk Kanishk was appointed as a Director was appointed as a Director on 05 Mar 2025 & has been associated with this company since 9 months 20 days . was documented.
Shyama Singh was appointed as a Additional Director was appointed as a Additional Director on 01 Jan 2020 & has been associated with this company since 5 years 11 months . was recorded as a recent event.
The activity A charge registered on 05 Aug 2014 via Charge ID 10516878 with Siemens Financial Services Private Limited was fully satisfied on 07 Nov 2017. was completed.
The CIN of Nanotek Remedies Private Limited is U24231MH2006PTC160936.
Nanotek Remedies Private Limited is headquartered at Row House 42-D, Mhada Complex, Near N.N.P. Zone 1 & 2, Off Film City Road, Goregoan East, ,, Mumbai, Maharashtra, 400065.
Nanotek Remedies Private Limited was incorporated on 03 April 2006.
The current directors of Nanotek Remedies Private Limited are
The primary industry of Nanotek Remedies Private Limited is Trade.
Nanotek Remedies Private Limited is unlisted.
The authorized capital of Nanotek Remedies Private Limited is ₹0.50 M, and the paid-up capital is ₹0.50 M.
The compliance status of Nanotek Remedies Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX